FIGURE
Fig. 2
- ID
- ZDB-FIG-250610-8
- Publication
- Gundersen et al., 2025 - Repurposing chlorpromazine for anti-leukaemic therapy with the drug-in-cyclodextrin-in-liposome nanocarrier platform
- Other Figures
- All Figure Page
- Back to All Figure Page
Fig. 2
HL-60 cells are unaffected by CDs and empty liposomes but sustain a dose-dependent reduction in viability when treated with CPZ and CD/CPZ liposome formulations. HL-60 cells were measured for viability relative to control after incubation for 48 h with either: A) cyclodextrins (CD), B) empty dehydration-rehydration vesicles (DRV), or C) either free chlorpromazine (CPZ), CPZ-loaded DRV, or DRV loaded with CD/CPZ complexes. The results are shown as the mean ± SD of four wells measured by metabolic conversion of the MTS reagent. |
Expression Data
Expression Detail
Antibody Labeling
Phenotype Data
Phenotype Detail
Acknowledgments
This image is the copyrighted work of the attributed author or publisher, and
ZFIN has permission only to display this image to its users.
Additional permissions should be obtained from the applicable author or publisher of the image.
Full text @ Carbohydr. Polym.